Diabetes drug useful for ovary disease

	Tweet

Treatment with the diabetes drug rosiglitazone, which is marketed under the trade name Avandia, can restore ovulation in obese women with polycystic ovary syndrome (PCOS), a disease involving high levels of male hormones resulting in fertility and menstrual problems, new research shows.

Metformin, another diabetes drug that can restore ovarian function, is associated with significant gastrointestinal side effects and is not effective in obese women with PCOS, Drs. Vicken Sepilian and Manubai Nagamani, from the University of Texas Medical Branch in Galveston, note.

They therefore tested rosiglitazone as an alternative treatment in 12 obese women with PCOS, according to the report in the Journal of Clinical Endocrinology and Metabolism. Unlike metformin, rosiglitazone belongs to a group of drugs called thiazolidinediones, which work by making the body more sensitive to insulin, the key hormone that lowers blood sugar levels.

Ovulation was restored in 11 of the 12 women, with spontaneous menstruation occurring within the first 3 months of treatment, the authors note. Moreover, a dramatic drop in blood levels of the potent male hormone testosterone occurred. As expected, the patients also experienced an improvement in their sensitivity to insulin.

Thiazolidinediones, the researchers conclude “may be the ideal treatment for obese PCOS women with (poor insulin sensitivity) who desire fertility.” However, they note that rosiglitazone should be discontinued if a patient becomes pregnant.

SOURCE: Journal of Clinical Endocrinology and Metabolism, October 2004.

RELATED STORIES:
More patients on Pfizer drug stop due to death-FDA   Hospital hygiene ‘improving’   US FDA clears Barr’s generic version of Allegra   Antidepressant promising for tension headaches   NitroMed drug cut deaths in blacks   Bristol-Myers arthritis drug promising in trial   Rare, drug-resistant HIV strain diagnosed in New York   Low-dose Glaxo bird flu vaccine seen ready in 2007   Short-Term Celebrex Safe Against Cirrhosis   Safe drug imports could be difficult - report   Study supports controversial blood-thinning drug   U.S. FDA nominee faces senators after Plan B move

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]